What the Study Found (In Plain English)
Published in Basic & clinical pharmacology & toxicology (2021), this randomized controlled trial evaluating human clinical outcomes investigated: Adipose tissue is the primary energy reservoir of the human body, which also possesses endocrine functions. Key clinical takeaway: In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P 0.08). In conclusion, despite liraglutide's effect on weight loss, sustained alterations in subcutaneous adipose tissue did not seem to appear.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Basic & clinical pharmacology & toxicology, 2021-06-15; Randomized Controlled Trial; Rigor 88/100): In comparison with placebo, liraglutide induced weight loss (3.38 kg, 95% CI -5.29; -1.48, P 0.08). In conclusion, despite liraglutide's effect on weight loss, sustained alterations in subcutaneous adipose tissue did not seem to appear.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.